A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

Area of Science:

• Cardiology
• Molecular Biology
• Biochemistry

Background:

• Pathologic stimuli induce myocardial hypertrophy, characterized by increased cell size and fetal gene activation.
• Cardiac hypertrophy is a significant risk factor for heart failure.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying cardiac hypertrophy.
• To identify novel therapeutic targets for preventing cardiac hypertrophy and heart failure.

Main Methods:

• Investigated the role of calcineurin and NF-AT3 in cardiac hypertrophy using molecular biology techniques.
• Utilized transgenic mouse models expressing activated calcineurin or NF-AT3.
• Examined the effects of calcineurin inhibition on hypertrophy in vitro and in vivo.

Main Results:

• Cardiac hypertrophy is induced by calcineurin-mediated dephosphorylation and nuclear translocation of NF-AT3.
• NF-AT3 interacts with GATA4, leading to synergistic activation of cardiac transcription.
• Transgenic mice with activated calcineurin or NF-AT3 developed cardiac hypertrophy and heart failure.
• Pharmacologic inhibition of calcineurin blocked hypertrophy.

Conclusions:

• Identified a novel calcineurin-NF-AT3-GATA4 signaling pathway in cardiac hypertrophy.
• Calcineurin inhibition represents a potential therapeutic strategy for preventing cardiac hypertrophy and heart failure.